EWU vs XBI
iShares MSCI United Kingdom ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for EWU.
- • EWU pays a higher dividend yield (3.14%).
Side-by-side metrics
| Metric | EWU | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.14% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $3.73B | $10.92B |
YTD return | 11.45% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.66 | 1.01 |
P/E ratio | 16.65 | — |
Last price | $47.78 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EWU top holdings
| SHEL.L | Shell PLC | 9.88% |
| HSBA.L | HSBC Holdings PLC | 9.30% |
| AZN.L | AstraZeneca PLC | 8.93% |
| ULVR.L | Unilever PLC | 4.44% |
| RR.L | Rolls-Royce Holdings PLC | 4.37% |
| BP.L | BP PLC | 4.17% |
| BATS.L | British American Tobacco PLC | 3.89% |
| GSK.L | GSK PLC | 3.17% |
| RIO.L | Rio Tinto PLC Ordinary Shares | 2.75% |
| NG.L | National Grid PLC | 2.64% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EWU
EWU (iShares MSCI United Kingdom ETF) is UK large and mid-cap equities. Managed by iShares, the fund carries $3.7B in assets under management, an expense ratio of 0.50%, a dividend yield of 3.14%. Its largest holding is Shell PLC (SHEL.L), which represents 9.9% of the portfolio. Real Estate is the fund's largest sector exposure at 0.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.